Zacks Investment Research Lowers Akero Therapeutics (NASDAQ:AKRO) to Sell

Share on StockTwits

Zacks Investment Research lowered shares of Akero Therapeutics (NASDAQ:AKRO) from a hold rating to a sell rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company’s product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which are in clinical stage. Akero Therapeutics Inc. is based in San Francisco, United States. “

Shares of NASDAQ AKRO opened at $19.69 on Thursday. Akero Therapeutics has a 52 week low of $16.06 and a 52 week high of $30.30. The business has a fifty day moving average price of $20.27.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.13). As a group, analysts anticipate that Akero Therapeutics will post -2.95 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Griffin Asset Management Inc. purchased a new position in shares of Akero Therapeutics in the second quarter worth $25,000. Strs Ohio purchased a new position in shares of Akero Therapeutics in the third quarter worth $29,000. Tower Research Capital LLC TRC purchased a new position in shares of Akero Therapeutics in the second quarter worth $26,000. Victory Capital Management Inc. purchased a new position in shares of Akero Therapeutics in the second quarter worth $31,000. Finally, Barclays PLC purchased a new position in shares of Akero Therapeutics in the third quarter worth $61,000. 44.63% of the stock is currently owned by institutional investors.

About Akero Therapeutics

Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.

Featured Article: What is the Hang Seng index?  

Get a free copy of the Zacks research report on Akero Therapeutics (AKRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.